{
  "trial_id": "NCT00490646",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, race, HER2 status, prior (neo)adjuvant chemotherapy, prior (neo)adjuvant trastuzumab, measurable disease status, Left Ventricular Ejection Fraction (LVEF), performance status, presence of significant cardiovascular disease, presence of brain metastases, baseline neuropathy grade.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex/Gender",
          "gender"
        ],
        [
          "Race/Ethnicity",
          "race"
        ],
        [
          "Number of participants who received prior chemotherapy in neoadjuvant/adjuvant setting",
          "prior (neo)adjuvant chemotherapy"
        ]
      ],
      "remaining_reference_features": [
        "Karnofsky Performance Status",
        "Menopausal Status"
      ],
      "remaining_candidate_features": [
        "HER2 status",
        "prior (neo)adjuvant trastuzumab",
        "measurable disease status",
        "Left Ventricular Ejection Fraction (LVEF)",
        "performance status",
        "presence of significant cardiovascular disease",
        "presence of brain metastases",
        "baseline neuropathy grade."
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, HER2 status, Prior (neo)adjuvant chemotherapy, Prior (neo)adjuvant trastuzumab, Measurable disease status, Left Ventricular Ejection Fraction (LVEF),",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex/Gender",
          "Sex: Female"
        ],
        [
          "Race/Ethnicity",
          "Race/Ethnicity"
        ],
        [
          "Number of participants who received prior chemotherapy in neoadjuvant/adjuvant setting",
          "Prior (neo)adjuvant chemotherapy"
        ]
      ],
      "remaining_reference_features": [
        "Karnofsky Performance Status",
        "Menopausal Status"
      ],
      "remaining_candidate_features": [
        "Male",
        "Region of Enrollment",
        "HER2 status",
        "Prior (neo)adjuvant trastuzumab",
        "Measurable disease status",
        "Left Ventricular Ejection Fraction (LVEF)"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Race/Ethnicity, Customized, Region of Enrollment, Eastern Cooperative Oncology Group (ECOG) Performance Status, Menopausal Status, Number of Metastatic Sites, Prior (Neo)Adjuvant Chemotherapy, Prior (Neo)Adjuvant Trastuzumab, Left Ventricular Ejection Fraction (LVEF), HER2 Status.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex/Gender",
          "Sex: Female"
        ],
        [
          "Race/Ethnicity",
          "Race/Ethnicity"
        ],
        [
          "Menopausal Status",
          "Menopausal Status"
        ],
        [
          "Number of participants who received prior chemotherapy in neoadjuvant/adjuvant setting",
          "Prior (Neo)Adjuvant Chemotherapy"
        ]
      ],
      "remaining_reference_features": [
        "Karnofsky Performance Status"
      ],
      "remaining_candidate_features": [
        "Region of Enrollment",
        "Eastern Cooperative Oncology Group (ECOG) Performance Status",
        "Number of Metastatic Sites",
        "Prior (Neo)Adjuvant Trastuzumab",
        "Left Ventricular Ejection Fraction (LVEF)",
        "HER2 Status"
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, body mass index (BMI), Eastern Cooperative Oncology Group (ECOG) performance status, menopausal status, hormone receptor status, HER2 status, prior (neo)adjuvant therapy, time since diagnosis, time since relapse, number of metastatic sites, presence of visceral metastases, Left Ventricular Ejection Fraction (LVEF).",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex/Gender",
          "sex"
        ],
        [
          "Race/Ethnicity",
          "race"
        ],
        [
          "Menopausal Status",
          "menopausal status"
        ],
        [
          "Number of participants who received prior chemotherapy in neoadjuvant/adjuvant setting",
          "prior (neo)adjuvant therapy"
        ]
      ],
      "remaining_reference_features": [
        "Karnofsky Performance Status"
      ],
      "remaining_candidate_features": [
        "ethnicity",
        "body mass index (BMI)",
        "Eastern Cooperative Oncology Group (ECOG) performance status",
        "hormone receptor status",
        "HER2 status",
        "time since diagnosis",
        "time since relapse",
        "number of metastatic sites",
        "presence of visceral metastases",
        "Left Ventricular Ejection Fraction (LVEF)."
      ]
    }
  }
}